Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | KIF11 | P52732 | 1/20 | 0.47 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.46 |
| ▸ | FADS1 | O60427 | 1/20 | 0.45 |
| ▸ | BRD4 | O60885 | 1/20 | 0.45 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.45 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13524566 | 0.92 | KIF11 (0.56) | KEAP1ALDH1A1SMN1; SMN2LMNAKIF11 | |
| SCHEMBL245468 | 0.85 | MEN1 (0.60) | KEAP1ALDH1A1SMN1; SMN2POLBMAPKAPK2 | |
| SCHEMBL244843 | 0.85 | KEAP1 (0.52) | KEAP1ALDH1A1SMN1; SMN2POLBMAPKAPK2 | |
| SCHEMBL13181439 | 0.85 | KDM1A (0.48) | ALDH1A1SMN1; SMN2CA2KDM4EEGFR | |
| SCHEMBL4370199 | 0.85 | KEAP1 (0.52) | KEAP1ALDH1A1SMN1; SMN2POLBMAPKAPK2 | |
| SCHEMBL14508412 | 0.85 | CA2 (0.55) | ALDH1A1SMN1; SMN2CA2KDM4EEGFR | |
| SCHEMBL22220775 | 0.84 | CA2 (0.47) | SMN1; SMN2CA2LMNAEGFRTNNI3K | |
| SCHEMBL27182647 | 0.84 | CA2 (0.50) | ALDH1A1SMN1; SMN2MAPKAPK2CA2KDM4E | |
| SCHEMBL698855 | 0.83 | KEAP1 (0.70) | KEAP1ALDH1A1SMN1; SMN2POLBKDM4E | |
| SCHEMBL21180002 | 0.83 | KIF11 (0.62) | ALDH1A1SMN1; SMN2LMNAKIF11BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240068009-A1 | SUBSTITUTED IMIDAZO[1,2-a]PYRAZINES AS LUCIFERASE SUBSTRATES | PROMEGA CORPORATION | 2024-02-29 | — | — | US | disclosed |
| WO-2024044757-A1 | AMINOPYRIMIDINE AND AMINOTRIAZINE DERIVATIVES AS MYC PROTEIN MODULATORS | Sanford Burnham Prebys Medical Discovery Institute (US) | 2024-02-29 | — | — | WO | disclosed |
| US-20240068009-A1 | SUBSTITUTED IMIDAZO[1,2-a]PYRAZINES AS LUCIFERASE SUBSTRATES | PROMEGA CORPORATION | 2024-02-29 | — | — | US | disclosed |
| US-11873291-B2 | Quinoline cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-20230357158-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2023-11-09 | — | — | US | disclosed |
| US-20230339871-A1 | COMPOUNDS AND METHODS OF MODULATING 17B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 | METREA BIOSCIENCES INC (US) | 2023-10-26 | — | — | US | disclosed |
| US-11781168-B2 | Process for preparing substituted imidazo[1,2-α]pyrazines | PROMEGA CORPORATION (US) | 2023-10-10 | — | — | US | disclosed |
| US-11781168-B2 | Process for preparing substituted imidazo[1,2-α]pyrazines | PROMEGA CORPORATION (US) | 2023-10-10 | — | — | US | disclosed |
| US-11771685-B2 | Compounds for the treatment of neurological or mitochondrial diseases | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2023-10-03 | — | — | US | disclosed |
| US-11771685-B2 | Compounds for the treatment of neurological or mitochondrial diseases | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2023-10-03 | — | — | US | disclosed |
| US-7897609-B2 | Aryl substituted imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2011-03-01 | — | — | US | disclosed |
| US-20110028464-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BOEHRINGER INGLEHEIM INTERNATIONAL GMBH (DE) | 2011-02-03 | — | — | US | disclosed |
| US-7803956-B2 | Benzofuran derivatives useful for treating hyper-proliferative disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2010-09-28 | — | — | US | disclosed |
| US-20100068204-A1 | 4-ARYLOXYQUINOLIN-2(1H)-ONES AS MTOR KINASE AND PI3 KINASE INHIBITORS, FOR USE AS ANTI-CANCER AGENTS | WYETH (US) | 2010-03-18 | — | — | US | disclosed |
| US-7659412-B2 | Benzofuran derivatives useful for treating hyper-proliferative disorders | BAYER HEALTHCARE LLC (US) | 2010-02-09 | — | — | US | disclosed |
| US-20090292014-A1 | BENZOFURAN DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS | ZHANG CHENGZHI | 2009-11-26 | — | — | US | disclosed |
| US-20090023783-A1 | BENZOFURAN DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS | ZHANG CHENGZHI | 2009-01-22 | — | — | US | disclosed |
| US-7420066-B2 | Benzofuran derivatives useful for treating hyper-proliferative disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-09-02 | — | — | US | disclosed |
| US-7417040-B2 | Fused tricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-08-26 | — | — | US | disclosed |
| US-7253158-B2 | Sulfonamides | HOFFMANN-LA ROCHE INC. (US) | 2007-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028464-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | RTF2, REV1, RTF1 | KEAP1 2682/4885ALDH1A1 3557/4885SMN1; SMN2 3906/4885 |
| US-11781168-B2 | Process for preparing substituted imidazo[1,2-α]pyrazines | CYP4Z1, CYP2E1, CYP2F1 | KEAP1 1432/4885ALDH1A1 170/4885SMN1; SMN2 2626/4885 |
| US-20090292014-A1 | BENZOFURAN DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS | PCNA, MKI67, CDK4 | KEAP1 1252/4885ALDH1A1 609/4885SMN1; SMN2 3770/4885 |
| US-11873291-B2 | Quinoline cGAS antagonist compounds | CGAS, GLS2, GLS | KEAP1 1295/4885ALDH1A1 4236/4885SMN1; SMN2 2633/4885 |
| US-11771685-B2 | Compounds for the treatment of neurological or mitochondrial diseases | MT-ND2, MT-ND1, NLN | KEAP1 257/4885ALDH1A1 739/4885SMN1; SMN2 137/4885 |
| US-20230357158-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | CGAS, GLS2, GLS | KEAP1 1295/4885ALDH1A1 4236/4885SMN1; SMN2 2633/4885 |
| US-20230339871-A1 | COMPOUNDS AND METHODS OF MODULATING 17B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 | HSD17B1, HSD17B13, HSD17B11 | KEAP1 1125/4885ALDH1A1 114/4885SMN1; SMN2 2284/4885 |
| US-20090023783-A1 | BENZOFURAN DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS | PCNA, MKI67, CDK4 | KEAP1 1252/4885ALDH1A1 609/4885SMN1; SMN2 3770/4885 |
| US-20240068009-A1 | SUBSTITUTED IMIDAZO[1,2-a]PYRAZINES AS LUCIFERASE SUBSTRATES | PGLS, AADAC, GLB1 | KEAP1 3109/4885ALDH1A1 1179/4885SMN1; SMN2 4438/4885 |
| US-20100068204-A1 | 4-ARYLOXYQUINOLIN-2(1H)-ONES AS MTOR KINASE AND PI3 KINASE INHIBITORS, FOR USE AS ANTI-CANCER AGENTS | MTOR, RICTOR, PIK3CA | KEAP1 360/4885ALDH1A1 2884/4885SMN1; SMN2 4072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.